病毒学
表面等离子共振
单域抗体
生物
中和
效力
抗原
融合蛋白
糖蛋白
单克隆抗体
抗体
分子生物学
病毒
化学
重组DNA
免疫学
体外
基因
材料科学
生物化学
纳米技术
纳米颗粒
作者
Ma,Michael Brecher,Allison Soufal,Tiziano Gaiotto,Sai Tian,Sumana Chandramouli,Vincent Dewar,Laurent Ferrant,Meng Zhang,Xianzhi Zhou,Varnika Roy
出处
期刊:Vaccine
[Elsevier]
日期:2023-05-01
卷期号:41 (21): 3308-3316
标识
DOI:10.1016/j.vaccine.2023.04.021
摘要
In the past decade, camelid nanobodies have been developed for multiple applications, including immuno-imaging, cancer immunotherapy, and antiviral therapeutics. Despite the prevalence of these approaches, nanobodies have rarely been used to assess the potency of vaccine antigen candidates, which are primarily based on mAb binding approaches. In this work, we demonstrate that a nanobody-based ELISA method is suitable for characterization of a leading respiratory syncytial virus (RSV) vaccine candidate, RSVPreF3. This nanobody, F-VHH-L66, compares similarly with AM14, an antibody well-known to be specific for the prefusion form of the RSV surface fusion glycoprotein, RSV F. ELISA assays based on F-VHH-L66 were specific for the trimeric, prefusion form of RSV F, the antigen conformation that best generates neutralizing antibodies. Additionally, the F-VHH-L66-based ELISA proved accurate, linear, and stability-indicating. Statistical analysis of 65 independent F-VHH-L66-based ELISA experiments indicated assay performance similar to that of ELISA assays based on AM14. Moreover, the binding kinetics of F-VHH-L66 to RSVPreF3 are comparable to those of AM14 when measured by surface plasmon resonance (SPR). Finally, F-VHH-L66 neutralized RSV(A) with similar efficacy as AM14; this bioactivity data further supports its use as an alternative to AM14 for pre-fusion specific structural characterization of RSVPreF3.
科研通智能强力驱动
Strongly Powered by AbleSci AI